TABLE 1.
Important metastasis‐related long non‐coding RNAs
| Metastasis‐related long non‐coding RNA | Cancer type | Function | Effect | Reference |
|---|---|---|---|---|
| H19 | Bladder cancer | Bind to enhancer of zeste homolog 2 (EZH2) to downregulate E‐cadherin | Inhibit | 255 |
| Prostate cancer | Encode miR‐675 to mediate the down‐regulation of TGF‐β1 | Promote | 258 | |
| Colorectal cancer | Upregulate zinc finger E‐box‐binding homeobox 1/2 protein | Promote | 257 | |
| PNUTS | Breast cancer | Competitive sponge for miR‐205 and miR‐200 and enhancing epithelial‐mesenchymal transition (EMT) | Promote | 259 |
| LINC00460 | Colon cancer | Enhance the expression of high‐mobility group AT‐hook 1 | Promote | 260 |
| Lnc01232 | Pancreatic cancer | Upregulate HNRNPA2B1, and activate the MAPK/ERK signaling | Promote | 261 |
| MALAT1 | Colorectal cancer | Regulate the miR‐106b‐5p via SLAIN2 | Promote | 262 |
| TPA | Breast Cancer | Activate TGF‐β signaling pathway | Promote | 263 |
| PVT1 | Colon Cancer | Downregulate tumor suppressor miR‐152‐3p | Promote | 264 |
| LIMT | Breast cancer | Suppress tumor cells motility | Inhibit | 265 |
| SPRY4‐IT1 | Bladder cancer | Bind to miR‐101‐3p to upregulate the expression of EZH2 | Promote | 266 |
| TRERNA1 | Gastric cancer | Regulating CDH1 to upregulate SNAI1 | Promote | 267 |
| NEF | Hepatocellular carcinoma | Suppress Wnt/β‐catenin signaling to activate expression of FOXA2 | Inhibit | 268 |
| HOXD‐AS1 | Hepatocellular carcinoma | Competitive bind to miR‐130a‐3p to upregulate the expression of EZH2 and MMP2 | Promote | 269 |
| CYTOR | Colon cancer | Activate Wnt/β‐catenin signaling to enhance EMT | Promote | 270 |
| JPX | Lung cancer | Activate Wnt/β‐catenin signaling pathway to upregulate Twist1 expression | Promote | 271 |
| LINC00662 | Colon cancer | Activate extracellular signal‐regulated kinase (ERK) signaling pathway | Promote | 272 |
| ID2‐AS1 | Hepatocellular carcinoma | Activate HDAC8/ID2 signaling pathway to decrease Twist expression | Inhibit | 273 |
| RPPH1 | Colorectal cancer | Interact with TUBB3 to reduce E‐cadherin levels and induce macrophages M2 polarization | Promote | 274 |
| SATB2‐AS1 | Colorectal cancer | Regulate SATB2 to decrease MMP9 and vimentin | Inhibit | 275 |
| NORAD | Lung cancer Breast cancer | Bind and sequester S100P to suppress S100P pro‐metastatic signaling pathway | Inhibit | 276 |
| URRCC | Renal cancer | Enhance EGFL7 expression to suppress P‐AKT/FOXO3 signaling pathway | Promote | 277 |
| FEZF1‐AS1 | Colorectal cancer | Activate PKM2/signal transducers and activators of transcription 3 signaling pathway | Promote | 278 |
| ADAMTS9‐AS2 | Salivary adenoid cystic carcinoma | Activate PI3K/Akt and MEK/ERK signaling pathway | Promote | 279 |
| GAS5 | Pancreatic cancer. | Regulate miR‐221/SOCS3 to suppress EMT and cancer stem cells self‐renewal | Inhibit | 280 |